<SEC-DOCUMENT>0001193125-20-294751.txt : 20201116
<SEC-HEADER>0001193125-20-294751.hdr.sgml : 20201116
<ACCEPTANCE-DATETIME>20201116160557
ACCESSION NUMBER:		0001193125-20-294751
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20201116
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20201116
DATE AS OF CHANGE:		20201116

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INOVIO PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001055726
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				330969592
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14888
		FILM NUMBER:		201316773

	BUSINESS ADDRESS:	
		STREET 1:		6769 MESA RIDGE RD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		8584103134

	MAIL ADDRESS:	
		STREET 1:		6769 MESA RIDGE RD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INOVIO BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20050404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20011116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL LTD
		DATE OF NAME CHANGE:	19980213
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d41811d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ino="http://www.inovio.com/20201116" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body>
 <div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2020-11-16_to_2020-11-16">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2020-11-16_to_2020-11-16">0001055726</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="ino-20201116.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2020-11-16_to_2020-11-16"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-11-16</xbrli:startDate> <xbrli:endDate>2020-11-16</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, DC 20549</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="duration_2020-11-16_to_2020-11-16">8-K</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2020-11-16_to_2020-11-16" format="ixt:datemonthdayyearen">November 16, 2020</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2020-11-16_to_2020-11-16">Inovio Pharmaceuticals, Inc.</ix:nonNumeric> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2020-11-16_to_2020-11-16" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2020-11-16_to_2020-11-16">001-14888</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2020-11-16_to_2020-11-16">33-0969592</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:99%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2020-11-16_to_2020-11-16">660 W. Germantown Pike</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2020-11-16_to_2020-11-16">Suite 110</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2020-11-16_to_2020-11-16">Plymouth Meeting</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2020-11-16_to_2020-11-16">PA</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2020-11-16_to_2020-11-16">19462</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of principal executive offices, including zip code)</span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2020-11-16_to_2020-11-16">(267)</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2020-11-16_to_2020-11-16">440-4200</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s telephone number, including area code)</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">N/A</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2020-11-16_to_2020-11-16" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2020-11-16_to_2020-11-16" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2020-11-16_to_2020-11-16" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2020-11-16_to_2020-11-16" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section 12(b) of the Act:</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2020-11-16_to_2020-11-16">Common Stock, $0.001 par value</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2020-11-16_to_2020-11-16">INO</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2020-11-16_to_2020-11-16" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#160;&#160;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2020-11-16_to_2020-11-16" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;8.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Events. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&#160;16, 2020, Inovio Pharmaceuticals, Inc. (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Company</span></span>&#8221;) issued a press release regarding the Company&#8217;s Phase 2/3 clinical trial for its <span style="white-space:nowrap">COVID-19</span> vaccine candidate <span style="white-space:nowrap">INO-4800.</span> A copy of this press release is attached as Exhibit 99.1 hereto and is incorporated by reference herein. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Forward-Looking Statements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This report contains certain forward-looking statements relating to the Company&#8217;s business that involve a number of risks and uncertainties, including statements related to expected development, funding and manufacturing of its CELLECTRA device and its vaccine candidate <span style="white-space:nowrap">INO-4800</span> and plans to resolve the remaining device questions. These statements may be identified by introductory words such as &#8220;may,&#8221; &#8220;expects,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;will,&#8221; &#8220;achieve,&#8221; &#8220;anticipate,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;subject to&#8221; or words of similar meaning, or by the fact that they do not relate strictly to historical or current facts. For such statements, the Company claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including those discussed in the &#8220;Risk Factors&#8221; section of the Company&#8217;s most recently filed Annual Report on Form <span style="white-space:nowrap">10-K</span> or Quarterly Report on Form <span style="white-space:nowrap">10-Q,</span> as well as other filings that the Company makes with the SEC from time to time. There can be no assurance that any of the forward-looking information provided herein will be proven accurate. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the forward-looking statements included in this report represent the Company&#8217;s views as of the date hereof. The Company anticipates that subsequent events and developments may cause its views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so, except as may be required by law. These forward-looking statements should not be relied upon as representing the Company&#8217;s views as of any date subsequent to the date of this report. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td style="width:92%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">&#160;&#160;&#160;&#160;No.&#160;&#160;&#160;&#160;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Exhibit Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d41811dex991.htm">Press Release, dated November&#160;16, 2020. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover page interactive data file (embedded within the Inline XBRL document).</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:3%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:45%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">INOVIO PHARMACEUTICALS, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Date: November&#160;16, 2020</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Peter Kies</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Peter Kies</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Chief Financial Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d41811dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g41811g1116212613251.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INOVIO Announces Initiation of Phase 2 Segment of its Phase 2/3 Clinical Trial for its <FONT
STYLE="white-space:nowrap">COVID-19</FONT> DNA Vaccine Candidate, <FONT STYLE="white-space:nowrap">INO-4800;</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Trial Will Be
Funded by the U.S. Department of Defense </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PLYMOUTH MEETING, PA &#150; November&nbsp;16, 2020 &#150; INOVIO (NASDAQ:INO), a biotechnology company
focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced that it has received clearance from the U.S. Food&nbsp;&amp; Drug Administration (FDA) to proceed with
the Phase 2 segment of its planned Phase 2/3 clinical trial for <FONT STYLE="white-space:nowrap">INO-4800,</FONT> its <FONT STYLE="white-space:nowrap">COVID-19</FONT> vaccine candidate. The planned Phase 2/3 clinical trial, called INNOVATE
(<B><U>IN</U></B>OVIO I<B><U>NO</U></B>-4800 <B><U>Va</U></B>ccine <B><U>T</U></B>rial for <B><U>E</U></B>fficacy), is a randomized, blinded, placebo-controlled safety and efficacy trial of <FONT STYLE="white-space:nowrap">INO-4800</FONT> to be
conducted in adults in the U.S. The INNOVATE trial will be funded by the U.S. Department of Defense (DoD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) in coordination with the Office of the
Assistant Secretary of Defense for Health Affairs (OASD (HA)) and the Defense Health Agency (DHA). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Phase 2 segment of the trial is designed to
evaluate safety, tolerability and immunogenicity of <FONT STYLE="white-space:nowrap">INO-4800</FONT> in a <FONT STYLE="white-space:nowrap">2-dose</FONT> regimen (1.0 mg or 2.0 mg), in a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">three-to-one</FONT></FONT> randomization to receive either <FONT STYLE="white-space:nowrap">INO-4800</FONT> or placebo for each dose to confirm the more appropriate dose(s) for each
of three age groups with high risks of infection <FONT STYLE="white-space:nowrap">(18-50</FONT> years, <FONT STYLE="white-space:nowrap">51-64</FONT> years and 65 years and older) for the subsequent Phase 3 efficacy evaluation. The Phase 3 segment of
the INNOVATE trial remains on partial clinical hold until INOVIO satisfactorily resolves the FDA&#146;s remaining questions related to the CELLECTRA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> 2000 device that will be used to deliver <FONT
STYLE="white-space:nowrap">INO-4800</FONT> directly into the skin. The company plans to resolve the remaining device questions during the conduct of Phase 2 segment and prior to the start of the Phase 3 segment of the trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;I am extremely proud of the INOVIO team, which has been working tirelessly to develop a safe and effective vaccine in the fight against the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic. Initiation of our Phase 2 trial marks a pivotal milestone for INO-4800,&#148; said INOVIO&#146;s President and CEO, Dr.&nbsp;J. Joseph Kim. &#147;We are especially pleased to continue our
partnership with the DoD to advance the development of INO-4800 for active duty service members and civilian personnel and are grateful for the Department&#146;s continued confidence in our technology to combat COVID-19.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr. Kim continued, &#147;INO-4800&#146;s key differentiators are the safety and tolerability data we have observed thus far, as well as its excellent
thermostability profile &#150; making it possible to manufacture at scale and transport without frozen cold chain requirements. INO-4800 also maintains the ability to be safely re-administered and is differentiated by its ability to stimulate both
CD4+ and CD8+ T cell responses.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA&#146;s authorization to proceed is based on its review of INOVIO&#146;s
<FONT STYLE="white-space:nowrap">non-clinical</FONT> data, device information and interim Phase 1 safety and immunogenicity data as well as its design and plans for the Phase 2 and Phase 3 segments of the planned clinical trial. The Phase 2 segment
of the trial is expected to enroll approximately 400 participants at up to 17 U.S. sites to evaluate safety and immunogenicity in order to confirm the dose(s) for the subsequent efficacy evaluation planned for the Phase 3 segment. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The DoD has agreed to provide funding for both the Phase 2 and Phase 3 segments of the INNOVATE clinical
trial, in addition to the $71<U></U> million of funding previously announced in June for the large-scale manufacture of the company&#146;s proprietary smart device CELLECTRA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> 3PSP and the
procurement of CELLECTRA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> 2000 devices. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About the
<FONT STYLE="white-space:nowrap">INO-4800</FONT> &#147;INNOVATE&#148; Phase 2/3 Clinical Trial </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The lead Principal Investigator for the INNOVATE trial
is Dr.<U></U>&nbsp;Pablo Tebas, Professor of Medicine at the Hospital of the University of Pennsylvania. The Phase 2 segment of the trial is designed to evaluate safety, tolerability and immunogenicity of INO-4800 in a 2-dose regimen (1.0 mg or 2.0
mg), in a three-to-one randomization to receive either INO-4800 or placebo for each dose, to confirm the more appropriate dose(s) for each of three age groups (18-50 years, 51-64 years and 65 years and older) for the subsequent Phase 3 efficacy
evaluation. The company intends to work diligently to ensure diversity in enrollment, targeting specific populations that are working or residing in environments with high infection rates and/or areas where there is greater risk of exposure to
SARS-CoV-2, for whom exposure may be relatively prolonged or for whom personal protective equipment (PPE) may be inconsistently used, especially in confined settings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the Phase 3 segment of the trial, INOVIO intends to enroll healthy men and non-pregnant women 18 years and older, to evaluate the efficacy of the proposed
dose(s) based on the data from the Phase 2 evaluation. Participants will be enrolled in a one-to-one randomization to receive either INO-4800 or a placebo. The Phase 3 segment will be case-driven with the final number of enrollees to be determined
by the incidence of COVID-19 during the Phase 3 segment. The primary endpoint of the Phase 3 segment will be virologically confirmed COVID-19 disease. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About INOVIO&#146;s Global Coalition Advancing <FONT STYLE="white-space:nowrap">INO-4800</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">INOVIO has assembled a global coalition of collaborators, partners and funders to rapidly advance the development of
<FONT STYLE="white-space:nowrap">INO-4800.</FONT> R&amp;D collaborators to date include the Wistar Institute, the University of Pennsylvania, the University of Texas, Fudan University and Laval University. INOVIO has partnered with Advaccine and the
International Vaccine Institute to conduct clinical trials of INO-4800 in China and South Korea, respectively. INOVIO is also assessing nonclinical efficacy of INO-4800 in several animal challenge models with Public Health England (PHE) and
Commonwealth Scientific and Industrial Research Organization (CSIRO) in Australia. INOVIO is working with a team of contract manufacturers including Thermo Fisher Scientific, Richter-Helm BioLogics, and Ology Bioservices to manufacture INO-4800 on a
commercial scale and is seeking additional external funding and partnerships to further scale up manufacturing capacities to satisfy the urgent global demand for safe and effective vaccines. To date, the Coalition for Epidemic Preparedness
Innovations (CEPI), the Bill<U></U>&nbsp;&amp; Melinda Gates Foundation, and the U.S. Department of Defense have contributed significant funding to the advancement and manufacturing of INO-4800. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About <FONT STYLE="white-space:nowrap">INO-4800</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">INO-4800 is INOVIO&#146;s DNA vaccine candidate intended to protect against SARS-CoV-2, the novel coronavirus that causes COVID-19. INOVIO has extensive
experience working with coronaviruses and was the first company to initiate a Phase 2a trial for INO-4700, a vaccine for Middle East Respiratory Syndrome (MERS), another coronavirus related to SARS-CoV-2. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">INO-4800</FONT> is the only nucleic-acid based vaccine that is stable at
room temperature for more than a year and does not need to be frozen in transport of storage, which are important factors when implementing mass immunizations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About INOVIO&#146;s DNA Medicines Platform </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">INOVIO has 15
DNA medicine clinical programs currently in development focused on HPV-associated diseases, cancer, and infectious diseases, including coronaviruses associated with MERS and COVID-19 diseases being developed under grants from the Coalition for
Epidemic Preparedness Innovations (CEPI) and the U.S. Department of Defense. DNA medicines are composed of optimized DNA plasmids, which are small circles of double-stranded DNA that are synthesized or reorganized by a computer sequencing technology
and designed to produce a specific immune response in the body. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">INOVIO&#146;s DNA medicines deliver optimized plasmids directly into cells
intramuscularly or intradermally using INOVIO&#146;s proprietary hand-held smart device called CELLECTRA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. The CELLECTRA device uses a brief electrical pulse to reversibly open small pores in
the cell to allow the plasmids to enter, overcoming a key limitation of other DNA and other nucleic acid approaches, such as mRNA. Once inside the cell, the DNA plasmids enable the cell to produce the targeted antigen. The antigen is processed
naturally in the cell and triggers the desired T cell and antibody-mediated immune responses. Administration with the CELLECTRA device ensures that the DNA medicine is efficiently delivered directly into the body&#146;s cells, where it can go to
work to drive an immune response. INOVIO&#146;s DNA medicines do not interfere with or change in any way an individual&#146;s own DNA. The advantages of INOVIO&#146;s DNA medicine platform are how fast DNA medicines can be designed and manufactured;
the stability of the products, which do not require freezing in storage and transport; and the robust immune response, safety profile, and tolerability that have been observed in clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With more than 2,000 patients receiving INOVIO investigational DNA medicines in more than 7,000 applications across a range of clinical trials, INOVIO has a
strong track record of rapidly generating DNA medicine candidates with potential to meet urgent global health needs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About INOVIO </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases,
cancer, and diseases associated with HPV. INOVIO is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body via a proprietary smart device to produce a robust and tolerable
immune response. Specifically, INOVIO&#146;s lead candidate VGX-3100, currently in Phase 3 trials for precancerous cervical dysplasia, destroyed and cleared high-risk HPV 16 and 18 in a Phase 2b clinical trial. High-risk HPV is responsible for 70%
of cervical cancer, 91% of anal cancer, and 69% of vulvar cancer. Also in development are programs targeting HPV-related cancers and a rare HPV-related disease, recurrent respiratory papillomatosis (RRP); non-HPV-related cancers glioblastoma
multiforme (GBM) and prostate cancer; as well as externally funded infectious disease DNA vaccine development programs in Zika, Lassa fever, Ebola, HIV, and coronaviruses associated with MERS and COVID-19 diseases. Partners and collaborators include
Advaccine, ApolloBio Corporation, AstraZeneca, The Bill&nbsp;&amp; Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA)/Joint Program Executive Office for Chemical,
Biological, Radiological and Nuclear Defense (JPEO-CBRND)/Department of Defense (DOD), HIV Vaccines Trial Network, International Vaccine Institute (IVI), Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of
Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Immunotherapy, Plumbline Life Sciences, Regeneron, Richter-Helm BioLogics, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute.
INOVIO also is a proud recipient of 2020 Women on Boards &#147;W&#148; designation recognizing companies with more than 20% women on their board of directors. For more information, visit <U>www.inovio.com. </U></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CONTACTS: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Media: Jeff Richardson, 267-440-4211,
<U>jrichardson@inovio.com</U> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors: Ben Matone, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">484-362-0076,</FONT></FONT>
<I><U></U></I><U>ben.matone@inovio.com<I></I></U><I></I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * * </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press release contains certain forward-looking statements relating to our business, including our plans to develop and manufacture DNA medicines, our
expectations regarding our research and development programs, including the planned initiation and conduct of the Phase 2/3 clinical trial of INO-4800, and our ability to successfully manufacture and produce large quantities of our product
candidates if they receive regulatory approval. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in preclinical studies, clinical trials, product
development programs and commercialization activities and outcomes, our ability to secure sufficient manufacturing capacity to mass produce our product candidates, the availability of funding to support continuing research and studies in an effort
to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA medicines, our ability to support our pipeline of DNA medicine products, the ability of our collaborators to attain development and commercial
milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the
conditions targeted by us or our collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that we and our collaborators hope to develop, issues involving product liability, issues involving
patents and whether they or licenses to them will provide us with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others
or can withstand claims of invalidity and whether we can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of our technology by potential
corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December<U></U>&nbsp;31, 2019, our Quarterly
Report on Form 10-Q for the quarter ended September<U></U>&nbsp;30, 2020 and other filings we make from time to time with the Securities and Exchange Commission. There can be no assurance that any product candidate in our pipeline will be
successfully developed, manufactured or commercialized, that final results of clinical trials will be supportive of regulatory approvals required to market products, or that any of the forward-looking information provided herein will be proven
accurate. Forward-looking statements speak only as of the date of this release, and we undertake no obligation to update or revise these statements, except as may be required by law. </I></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>ino-20201116.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2020-6 Build:20200922.5 -->
<!-- Creation date: 11/17/2020 1:46:47 AM Eastern Time -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2019-01-31"
  xmlns:ino="http://www.inovio.com/20201116"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.inovio.com/20201116"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2019-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2011-01-31" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20201116_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20201116_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.inovio.com//20201116/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>ino-20201116_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2020-6 Build:20200922.5 -->
<!-- Creation date: 11/17/2020 1:46:47 AM Eastern Time -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>ino-20201116_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2020-6 Build:20200922.5 -->
<!-- Creation date: 11/17/2020 1:46:47 AM Eastern Time -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.inovio.com//20201116/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="ino-20201116.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.inovio.com//20201116/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g41811g1116212613251.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g41811g1116212613251.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !V 4(# 2(  A$! Q$!_\0
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MVR8]N7/\EKTJ*-(8DBC4)&@"JHZ "O.?ALIO-:U?4I.7/&3_ +;%C_(5Z30
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M?UYGFP?)-2OJWK_7D>DT4V.2.5 \;JZ'HRG(-.KRST@HHI&944LS!5'4DX%
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MK 1_RS#!<X_,UH?V<W_0RW?_ '\3_"@#H**Y34+F:+5+#29-7DMK5[<R&[)
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
F4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>d41811d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ino-20201116.xsd" xlink:type="simple"/>
    <context id="duration_2020-11-16_to_2020-11-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2020-11-16</startDate>
            <endDate>2020-11-16</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2020-11-16_to_2020-11-16">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2020-11-16_to_2020-11-16"
      id="Hidden_dei_EntityCentralIndexKey">0001055726</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2020-11-16_to_2020-11-16">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2020-11-16_to_2020-11-16">2020-11-16</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2020-11-16_to_2020-11-16">Inovio Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2020-11-16_to_2020-11-16">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2020-11-16_to_2020-11-16">001-14888</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2020-11-16_to_2020-11-16">33-0969592</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2020-11-16_to_2020-11-16">660 W. Germantown Pike</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2020-11-16_to_2020-11-16">Suite 110</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2020-11-16_to_2020-11-16">Plymouth Meeting</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2020-11-16_to_2020-11-16">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2020-11-16_to_2020-11-16">19462</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2020-11-16_to_2020-11-16">(267)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2020-11-16_to_2020-11-16">440-4200</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2020-11-16_to_2020-11-16">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2020-11-16_to_2020-11-16">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2020-11-16_to_2020-11-16">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2020-11-16_to_2020-11-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2020-11-16_to_2020-11-16">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2020-11-16_to_2020-11-16">INO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2020-11-16_to_2020-11-16">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2020-11-16_to_2020-11-16">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140221928519944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 16, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001055726<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 16,  2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Inovio Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-14888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0969592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">660 W. Germantown Pike<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Plymouth Meeting<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(267)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">440-4200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">INO<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( +R <%$'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " "\@'!1<>L;ONX    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M:L,P#(9?9?B>R$Y)#B;-I6.G#08K;.QF;+4UBQ-C:R1]^SE>FS*V!]C1TN]/
MGT"M]E*/ 9_#Z#&0Q7@WNWZ(4OLM.Q%Y"1#U"9V*94H,J7D8@U.4GN$(7ND/
M=42H.&_ (2FC2,$"+/Q*9%UKM-0!%8WA@C=ZQ?O/T&>8T8 ].APH@B@%L&Z9
MZ,]SW\(-L, (@XO?!30K,5?_Q.8.L$MRCG9-3=-43IN<2SL(>'MZ?,GK%G:(
MI :-Z5>TDLX>M^PZ^76SN]\_L*[B%2^$*$2S%XWDM:SK]\7UA]]-V(W&'NP_
M-KX*=BW\NHON"U!+ P04    " "\@'!1F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M +R <%$!3*;4500  .P0   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MG9A=<^(V%(:OM[]"P_2BG4FP9;YW"#.$)%MF-\0-M)EIIQ?"%J")+;FRS,>_
M[Y$A-MV:8Z8W8!F?UX^DH_=(#'=*OZ<;S@W9QY%,[QH;8Y+/CI,&&QZSM*D2
M+N&7E=(Q,]#4:R=--&=A'A1'CN>Z72=F0C9&P_R>KT=#E9E(2.YKDF9QS/3A
MGD=J=]>@C8\;KV*],?:&,QHF;,WGW/R6^!I:3J$2BIC+5"A)-%_=-<;T\[W7
ML0'Y$[\+ODO/KHGMRE*I=]N8AG<-UQ+QB ?&2C#XVO()CR*K!!Q_GT0;Q3MM
MX/GUA_I3WGGHS)*E?**B-Q&:S5VCWR A7[$L,J]J]PL_=2@'#%24YI]D=WRV
M[39(D*5&Q:=@((B%/'ZS_6D@S@):]$* =PKP<N[CBW+*!V;8:*C5CFC[-*C9
MB[RK>33 "6EG96XT_"H@SHP>5)#!(!O"9$@>I1'F0*;R.-LP:D/'P$OLHTYP
M$KP_"GH7!&=JVR2T>T,\UW/_'>X 6P'H%8!>KM>ZH#=16Z[)G^-E:C1,X5^(
M9*N0;.62[0N28^APF'?Z*6+KJB[B\2L6I1SA:!<<;53G--P3(-$L@F$/^9Y\
MY8<J(ES)=5WJ=CH]KXM@=0JL#BI6I,3BD/ J%CR\?_L5@>@6$-WK('RNA;*I
M&1)(\$H>7.DC(7_X]*DF)7L%6^^:>7OE:V&3$B!G+*XDPW6F4FV%(OZ&P6H+
M>&9$ )EU XD0-!',?H'9OP83U)1.E,[7,YD;&$0R41GD'*2>"BNY<>&'1X1N
M4- -KJ%[$A$GLRQ><ET%@FM UM_2=K_?1WBH6SJA>PW1@NW)-(34$RN8CWS0
M+O/52+9:M^Z@.^@,/(SPS*OI-83C,-0\A40Y79!O\!QYD95362/9[;KDK4F^
M<$A!:=1.$E^\8^9&2^.FWO^G7>Q4)2TN.<\$9"^EV"JF91F@N(]_#SBQ+:7)
M H:A$@Z7\Z-##/N>#7F&8BSD&F,L2P2]JD84C,?U"Y"^!O.00?6<XYK^&$,K
MRP3%C?Y[-%^E!LK8'R*YZ"LUBG30[J(KI:P>%#?]?"K'L$V]C((+_.1U>S]C
M*&6QH+C+?U/@ZF#R2F)&5R/2;KNW;=AI8T1E7:"X?[]I80R7,#1QG,F3R:65
M5+A0W4:(EL6 XDX^5Y$(A%TUY!D27 L65?+@*G4\7ED+/-RX?<WSX>&PPHY[
M(=@RPC[T9;6JGK\:O5JRL@9XN&'_AVR:IAF0U0+BLK6 9_OU&H_F0:;M\J/>
MDBR$B2J77XV([6&^6U'!^PWYT6U"J2<)TV3+H@SE+-W?P^UZH5EH\VU^B)>J
M,MMJ!*:S%PRDM'@/M^-BP![WP8;)-;^XG:P1FHWG#^-?,:;2V[VKO/TQYGIM
M!^D+*$!E@VE)F*P\H-0(7LPOY^SL:O\'>&;VC2F)^ J$W&8/=/7Q:'UL&)7D
MQ]FE,G XSB\WG$'NVP?@]Y52YJ-A3\C%'QRC?P!02P,$%     @ O(!P48.I
MI0/4 0  ,@8   T   !X;"]S='EL97,N>&ULU57;BM1 $/V5IC_ GD1V04D"
M*BP(*@L[#[YVDDK2T#<[E3'9K[<[G=NX#*@/HB^3.J>J3YV^3M;C).&I T R
M*JG[G':(]BUC?=6!XOTK8T'[3&.<XNBA:UEO'?"Z#X.49.GI=,\4%YH6F1[4
M@\*>5&;0F-,39476&+TSKVDD?"E70"Y<YO0#EZ)T8J[E2L@ITFD@*B.-(^BM
M0$Z3P/3/,9U$%%PN.DIHXP+)8H?X6R[E/R56U'LHI-P,IC02168Y(CC]X,%<
M/),O4F2)SY/U#EO'IR2]H_N ^>.;E,;5X+8V"5VI(I/0!#M.M%WXHK$L)!&-
M\D$M>&LTGSVL(Y; RU8@Y5/8PJ_-E?;8D+@7'^NP#21,=0V]H26,,A$$_:-:
MU#[(WOV1++'B8O#]X&>C9_QM, B/#AHQSGALMOZWU)/;ZMQ:.;V3HM4*XMQ_
MN6&1\74<Z8P3S[Y;."F5)\!1<@&'HCHRWQVW9QAQ/4UC<]MS^A]Z_KOKW((&
MQ^71M#_Z__(J_XYCMMR>PQ6]NJ ;2\)#F-,OX7V5NP=2#D*BT OJ1%V#?G%/
MO3SRTC_@5_J^OH:&#Q+/6S*G>_P9:C&H-UO58UB7I6J//X7W*+F?&^[_$L4/
M4$L#!!0    ( +R <%&7BKL<P    !,"   +    7W)E;',O+G)E;'.=DKEN
MPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE
M[3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]
M9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIX
MT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T
M_C6"R0_L?@!02P,$%     @ O(!P41PX9>H_ 0  / (   \   !X;"]W;W)K
M8F]O:RYX;6R-4<MNPD ,_)75?D 34(M41+B4/I"J%I6*^Y)UB,4^(J\#+5]?
M)U%4I%YZ\GILC6=F%^=(QWV,1_7E74B%KIF;>9:EL@9OTDUL(,BDBN0-2TN'
M+#4$QJ8:@+W+IGD^R[S!H)>+D6M#V743&4K&& 3L@!W".?W.NU:=,.$>'?)W
MH?NW ZT\!O1X 5OH7*M4Q_-+)+S$P,9M2XK.%7HR#'9 C.4?>-N)_#3[U"-L
M]A]&A!1ZE@MAA92XW^CYC6@\@2P/7<OQ"1T#K0S#,\6VP7#H:,1%=F6CSV&L
M0XAS^D^,L:JPA%4L6P^!AQP)7"<PI!J;I%4P'@H]KB@3K'H,+"&I=1BH9+=S
M*J?7=G#-(O<J0YJC#&AM!^&C6@L5!K!O<B )+LF5&U)=Z7FFMW>3>TFH=>Y!
ML/?P&HT=S8\?M_P!4$L#!!0    ( +R <%$D'INBK0   /@!   :    >&PO
M7W)E;',O=V]R:V)O;VLN>&UL+G)E;'.UD3T.@S ,A:\2Y0 U4*E#!4Q=6"LN
M$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_[\E.GV@4=VZ@MO,D1FL&RF3+[.\ I%NT
MBB[.XS!/:A>LXEF&!KS2O6H0DBBZ0=@S9)[NF:*<//Y#='7=:7PX_;(X\ \P
MO%WHJ45D*4H5&N1,PFBV-L%2XLM,EJ*H,AF**I9P6B#BR2!M:59]L$].M.=Y
M%S?W1:[-XPFNWPQP>'3^ 5!+ P04    " "\@'!199!YDAD!  #/ P  $P
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M@6)8YL_X>\87_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0    ( +R
M<%$'04UB@0   +$    0              "  0    !D;V-0<F]P<R]A<' N
M>&UL4$L! A0#%     @ O(!P47'K&[[N    *P(  !$              ( !
MKP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ O(!P49E<G",0!@
MG"<  !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"
M% ,4    " "\@'!1 4RFU%4$  #L$   &               @($-"   >&PO
M=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ O(!P48.II0/4 0
M,@8   T              ( !F P  'AL+W-T>6QE<RYX;6Q02P$"% ,4
M" "\@'!1EXJ[',     3 @  "P              @ &7#@  7W)E;',O+G)E
M;'-02P$"% ,4    " "\@'!1'#AEZC\!   \ @  #P              @ &
M#P  >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ O(!P420>FZ*M    ^ $
M !H              ( ![!   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M4$L! A0#%     @ O(!P4660>9(9 0  SP,  !,              ( !T1$
J %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  &Q,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d41811d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com//20201116/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d41811d8k.htm">d41811d8k.htm</File>
    <File>d41811dex991.htm</File>
    <File>ino-20201116.xsd</File>
    <File>ino-20201116_lab.xml</File>
    <File>ino-20201116_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d41811d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d41811d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ino-20201116_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ino-20201116_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "ino-20201116.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "ino",
   "nsuri": "http://www.inovio.com/20201116",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d41811d8k.htm",
      "contextRef": "duration_2020-11-16_to_2020-11-16",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.inovio.com//20201116/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d41811d8k.htm",
      "contextRef": "duration_2020-11-16_to_2020-11-16",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com//20201116/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com//20201116/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com//20201116/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com//20201116/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com//20201116/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com//20201116/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com//20201116/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com//20201116/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com//20201116/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com//20201116/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com//20201116/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com//20201116/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com//20201116/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com//20201116/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com//20201116/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com//20201116/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com//20201116/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com//20201116/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com//20201116/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com//20201116/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com//20201116/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com//20201116/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com//20201116/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001193125-20-294751-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-20-294751-xbrl.zip
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MI9.D3 UV ?=5++]*L4B//OW47C<R5H5G<C7#YN"+>CN[(ID),'^//Y&-8#W
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M5PFT3K)S)UW@A!@W$S*G=('U+3(@$K(7J2_6C55H)U"/KFHUP,]8: X$%MJ
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M5N*Z.*!K*?GQZ>IK*-+HU , 0MV*HM3&05V^5YJ%MMH2?K^+VZS%_BA.^QB
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M.6'>E[M]7E.AHC%!)%\*!5F=;W#BYV.B#/_DVO]^Z#W6?BFMJ@N)))=U^\4
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M,61E>#DY,2YH=&U02P$"% ,4    " "\@'!1>4R<>V #   >#   $
M        @ $Z*P  :6YO+3(P,C Q,3$V+GAS9%!+ 0(4 Q0    ( +R <%&]
M5>NJA 8  $I'   4              "  <@N  !I;F\M,C R,#$Q,39?;&%B
M+GAM;%!+ 0(4 Q0    ( +R <%$7F,.SQ00  ,LL   4              "
M 7XU  !I;F\M,C R,#$Q,39?<')E+GAM;%!+!08     !0 % #L!  !U.@
"   !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
